The Manufacturers Life Insurance Company Has $2.12 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

The Manufacturers Life Insurance Company reduced its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 16.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,602 shares of the company's stock after selling 15,785 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.10% of IDEAYA Biosciences worth $2,123,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDYA. FMR LLC raised its position in shares of IDEAYA Biosciences by 2.6% in the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after buying an additional 327,498 shares during the last quarter. Vanguard Group Inc. increased its position in shares of IDEAYA Biosciences by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after acquiring an additional 282,936 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of IDEAYA Biosciences by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after purchasing an additional 43,226 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of IDEAYA Biosciences by 2.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock valued at $49,891,000 after purchasing an additional 46,931 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of IDEAYA Biosciences by 22.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock valued at $30,842,000 after buying an additional 220,000 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Trading Up 0.6%

Shares of IDYA traded up $0.10 during midday trading on Friday, reaching $17.41. 163,102 shares of the company were exchanged, compared to its average volume of 992,716. The stock has a 50-day moving average price of $17.65 and a 200-day moving average price of $22.35. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -5.28 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the firm earned ($0.53) earnings per share. Equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.